Drug-drug interactions with cannabidiol (CBD) appear to have no effect on treatment response in an open-label Expanded Access Program.

导出 LinkOut

翻译打印收藏纠错

第一作者： Tyler E,Gaston

第一单位： Department of Neurology, Division of Epilepsy, University of Alabama at Birmingham, Birmingham, AL, USA; Division of Neurology, Birmingham Veterans Affairs Medical Center, Birmingham, AL, USA. Electronic address: tegaston@uabmc.edu.

作者： Tyler E,Gaston ^[1] ; E Martina,Bebin ^[2] ; Gary R,Cutter ^[3] ; Steve B,Ampah ^[3] ; Yuliang,Liu ^[3] ; Leslie P,Grayson ^[4] ; Jerzy P,Szaflarski ^[2] ; UAB CBD Program

作者单位： Department of Neurology, Division of Epilepsy, University of Alabama at Birmingham, Birmingham, AL, USA; Division of Neurology, Birmingham Veterans Affairs Medical Center, Birmingham, AL, USA. Electronic address: tegaston@uabmc.edu. ^[1] Department of Neurology, Division of Epilepsy, University of Alabama at Birmingham, Birmingham, AL, USA. ^[2] Department of Biostatistics, University of Alabama at Birmingham School of Public Health, Birmingham, AL, USA. ^[3] Department of Neurology, Division of Epilepsy, University of Alabama at Birmingham, Birmingham, AL, USA; Division of Neurology, Birmingham Veterans Affairs Medical Center, Birmingham, AL, USA. ^[4]

关键词 Antiepileptic drugs Cannabidiol Clobazam Drug interactions Treatment-resistant epilepsy